Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Novus Medical Detox Center: DEA Must Enforce Drug Laws as Prescription Opioid Deaths Continue to Rise
  • USA - English


News provided by

JoTo PR

Apr 24, 2017, 08:00 ET

Share this article

Share toX

Share this article

Share toX

Bryn Wesch, CFO of Novus Medical Detox Center, discusses the DEA and the struggles to control opioid use in America.
Bryn Wesch, CFO of Novus Medical Detox Center, discusses the DEA and the struggles to control opioid use in America.

Though DEA officials and pharmaceutical companies cite ongoing efforts to prevent diversion, the perpetual rise in prescription opioid overdose deaths demands a much tougher approach and stiffer penalties.

Post this

NEW PORT RICHEY, Fla. (PRWEB) April 24, 2017 -- According to the U.S. Centers for Disease Control and Prevention (CDC), rising prescription opioid overdose deaths now claim the lives of 62 Americans each day.(1) Yet since 2011, the Drug Enforcement Administration (DEA) has slashed its civil case filings against drug manufacturers, distributors, pharmacies and prescribers by more than half.(2) Novus Medical Detox Center, a leading Florida-based drug treatment facility, exhorts the DEA to take immediate action to enforce federal laws, prevent diversion and protect U.S. citizens from the growing prescription opioid epidemic.

CDC data reveals overdose deaths from prescription opioid analgesics—including natural, semi-synthetic and synthetic forms—exceeded 22,000 in 2015, surpassing 2014’s previous record high of nearly 19,000 deaths.(1) While the death toll has continued to rise, a number of former DEA supervisors charge that agency officials “began delaying and blocking enforcement actions” in recent years. From 2011 to 2014, DEA civil case filings against drug manufacturers, distributors, pharmacies and doctors fell from 131 to 40 per year; and though 64 cases were filed as of October 2016, that number is still less than half of the 2011 total.(2)

“The DEA is charged with enforcing drug laws and regulations and ensuring those involved in illicit trafficking are brought to justice. Yet recent investigative reports suggest the DEA is failing to hold pharmaceutical firms accountable for their role in contributing to the current opioid crisis,” asserted Bryn Wesch, CFO of Novus Medical Detox Center. “DEA staff have expressed frustration over policy changes that make it more difficult to advance cases against pharmaceutical purveyors. Meanwhile, drug companies have hired former DEA and Justice Department officials to act on their behalf, and they’ve successfully lobbied Congress to pass laws that give them greater protection while placing a heavier burden on DEA agents.”

Several retired DEA supervisors told The Washington Post about cases that “languished for years without action.”(2) More recently, the Post reported on a case in which federal investigators found that lack of due diligence by Mallinckrodt Pharmaceuticals—one of the nation’s largest oxycodone manufacturers—“could have resulted in nearly 44,000 federal violations and exposed it to $2.3 billion in fines” for failing to report suspicious activity that suggested illegal diversion. But after six years, four investigations and the threat of billions in fines, Mallinckrodt is avoiding legal action after having negotiated a reported $35 million settlement, which one government official dismissed as “chump change” for a company that posted $3.4 billion in revenue and $489 million in profits last year.(3)

“Though DEA officials and pharmaceutical companies cite ongoing efforts to prevent diversion, the perpetual rise in prescription opioid overdose deaths demands a much tougher approach and stiffer penalties,” stated Wesch. “Unless DEA agents and prosecutors have the authority and support they need to crack down on those enabling illegal diversion, drug manufacturers and distributors will continue to put profits before people.”

Wesch calls for government officials and Congress to create, pass and uphold laws that address overprescribing and diversion, and she urges DEA leadership to re-examine and revise any policies that undermine agents’ ability to enforce laws and pursue cases against noncompliant drug manufacturers and distributors. She also maintains that legal consequences and fines should be quickly and consistently applied to companies that fail to report suspicious activity or are found to be complicit in black-market diversion of prescription medications.

Finally, Wesch proposes that any fines levied against pharmaceutical manufacturers and distributors should help fund expanded drug education, prevention and treatment programs. “Companies that have contributed to and profited from the prescription opioid epidemic should be required to play a role in solving it,” she noted. “Prescription medications have led many patients to develop substance use disorders. Proceeds from pharmaceutical industry fines can help these individuals obtain the care they need to manage the pain of opioid withdrawal, overcome dependency and achieve successful long-term recovery.”

For more information on Novus Medical Detox Center and its medically supervised prescription opioid treatment programs, visit https://novusdetox.com.

About Novus Medical Detox Center:
Novus Medical Detox Center has earned The Joint Commission’s Gold Seal of Approval for Behavioral Health Care Accreditation as an inpatient medical detox facility. Licensed by the Florida Department of Children and Families, Novus provides safe, effective alcohol and drug treatment programs that are based on proven medical protocols and designed to minimize the discomfort of withdrawal. The facility is located on 3.25 acres in New Port Richey, Florida, in a tranquil, spa-like setting bordering protected conservation land. Intent on proving that detox doesn’t have to be painful or degrading, Novus set out to transform the industry by bringing humanity into medical detox with individually customized treatment programs and 24/7 access to nursing care and withdrawal specialists. Today, Novus is renowned as a champion of industry standardization and a staunch advocate of patients fighting to overcome substance use disorders. Frequently recognized for its contributions to the industry and local community, Novus has become a regular source to media publications such as The Wall Street Journal and USA Today, and has ranked in the Tampa Bay Business Journal’s Fast 50, the Florida Business Journal’s Top 500 and the Inc. 5000 list of America’s fastest-growing companies. For more information on Novus’ medically supervised detox programs visit https://novusdetox.com.

1. Centers for Disease Control and Prevention. “Opioid Overdose: Opioid Data Analysis”; CDC website content; last updated February 9, 2017; accessed April 12, 2017. cdc.gov/drugoverdose/data/analysis.html

2. Bernstein, Lenny and Scott Higham. “Investigation: The DEA Slowed Enforcement While the Opioid Epidemic Grew Out of Control”; The Washington Post; October 22, 2016. washingtonpost.com/investigations/the-dea-slowed-enforcement-while-the-opioid-epidemic-grew-out-of-control/2016/10/22/aea2bf8e-7f71-11e6-8d13-d7c704ef9fd9_story.html

3. Bernstein, Lenny and Scott Higham. “The Government’s Struggle to Hold Opioid Manufacturers Accountable”; The Washington Post; April 2, 2017. washingtonpost.com/graphics/investigations/dea-mallinckrodt

Karla Jo Helms, JoTo PR, +1 (888) 202-4614 Ext: 802, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.